132 related articles for article (PubMed ID: 31874658)
1. [Effect of bevacizumab in treatment of children with optic pathway glioma].
Wu WS; Liu JJ; Sun YL; DU SX; Li CD; Li M; Ren SQ; Zhang J; Gong XJ; Sun LM
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Dec; 21(12):1193-1197. PubMed ID: 31874658
[TBL] [Abstract][Full Text] [Related]
2. Long-term visual outcome after chemotherapy for optic pathway glioma in children: Site and age are strongly predictive.
Dodgshun AJ; Elder JE; Hansford JR; Sullivan MJ
Cancer; 2015 Dec; 121(23):4190-6. PubMed ID: 26280460
[TBL] [Abstract][Full Text] [Related]
3. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program.
Dalla Via P; Opocher E; Pinello ML; Calderone M; Viscardi E; Clementi M; Battistella PA; Laverda AM; Da Dalt L; Perilongo G
Neuro Oncol; 2007 Oct; 9(4):430-7. PubMed ID: 17704361
[TBL] [Abstract][Full Text] [Related]
4. Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy-Analysis of a French pediatric historical cohort.
Rakotonjanahary J; Gravier N; Lambron J; De Carli E; Toulgoat F; Delion M; Pellier I; Rialland X
PLoS One; 2019; 14(3):e0212107. PubMed ID: 30849081
[TBL] [Abstract][Full Text] [Related]
5. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT
Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213
[TBL] [Abstract][Full Text] [Related]
6. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma.
Kaliki S; Shields CL; Shah SU; Eagle RC; Shields JA; Leahey A
Arch Ophthalmol; 2011 Nov; 129(11):1422-7. PubMed ID: 22084213
[TBL] [Abstract][Full Text] [Related]
7. Visual outcome following chemotherapy for progressive optic pathway gliomas.
Shofty B; Ben-Sira L; Freedman S; Yalon M; Dvir R; Weintraub M; Toledano H; Constantini S; Kesler A
Pediatr Blood Cancer; 2011 Sep; 57(3):481-5. PubMed ID: 21241008
[TBL] [Abstract][Full Text] [Related]
8. The effect of chemotherapy on optic pathway gliomas and their sub-components: A volumetric MR analysis study.
Shofty B; Mauda-Havakuk M; Weizman L; Constantini S; Ben-Bashat D; Dvir R; Pratt LT; Joskowicz L; Kesler A; Yalon M; Ravid L; Ben-Sira L
Pediatr Blood Cancer; 2015 Aug; 62(8):1353-9. PubMed ID: 25858021
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review.
Yamasaki F; Takano M; Yonezawa U; Taguchi A; Kolakshyapati M; Okumichi H; Kiuchi Y; Kurisu K
Childs Nerv Syst; 2020 Mar; 36(3):635-639. PubMed ID: 31701281
[TBL] [Abstract][Full Text] [Related]
10. Mortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy.
Rakotonjanahary J; De Carli E; Delion M; Kalifa C; Grill J; Doz F; Leblond P; Bertozzi AI; Rialland X;
PLoS One; 2015; 10(6):e0127676. PubMed ID: 26098902
[TBL] [Abstract][Full Text] [Related]
11. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence.
Moreno L; Bautista F; Ashley S; Duncan C; Zacharoulis S
Eur J Cancer; 2010 Aug; 46(12):2253-9. PubMed ID: 20400294
[TBL] [Abstract][Full Text] [Related]
12. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
Gnekow AK; Kortmann RD; Pietsch T; Emser A
Klin Padiatr; 2004; 216(6):331-42. PubMed ID: 15565548
[TBL] [Abstract][Full Text] [Related]
13. Vascular stenosis in a child with visual pathway glioma treated with bevacizumab: a case report and review of literature.
Pilotto C; Beshlawi I; Thomas A; Grundy RG
Childs Nerv Syst; 2018 Apr; 34(4):781-785. PubMed ID: 29249070
[TBL] [Abstract][Full Text] [Related]
14. [HIT-LGG: effectiveness of carboplatin-vincristine in progressive low-grade gliomas of childhood--an interim report].
Gnekow AK; Kaatsch P; Kortmann R; Wiestler OD
Klin Padiatr; 2000; 212(4):177-84. PubMed ID: 10994547
[TBL] [Abstract][Full Text] [Related]
15. Visual acuity of children treated with chemotherapy for optic pathway gliomas.
Kalin-Hajdu E; Décarie JC; Marzouki M; Carret AS; Ospina LH
Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233
[TBL] [Abstract][Full Text] [Related]
16. Treatments for astrocytic tumors in children: current and emerging strategies.
Burzynski SR
Paediatr Drugs; 2006; 8(3):167-78. PubMed ID: 16774296
[TBL] [Abstract][Full Text] [Related]
17. Optic pathway hypothalamic gliomas in children under three years of age: the role of chemotherapy.
Silva MM; Goldman S; Keating G; Marymont MA; Kalapurakal J; Tomita T
Pediatr Neurosurg; 2000 Sep; 33(3):151-8. PubMed ID: 11096362
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of carboplatin plus vincristine in an optic pathway glioma.
Moschovi M; Alexiou GA; Papakonstantopoulou I; Gavra M; Sfakianos G; Prodromou N
Klin Padiatr; 2010 Nov; 222(6):395-6. PubMed ID: 20806167
[No Abstract] [Full Text] [Related]
19. Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas.
Kelly JP; Leary S; Khanna P; Weiss AH
Ophthalmology; 2012 Jun; 119(6):1231-7. PubMed ID: 22364864
[TBL] [Abstract][Full Text] [Related]
20. Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1.
Campagna M; Opocher E; Viscardi E; Calderone M; Severino SM; Cermakova I; Perilongo G
Pediatr Blood Cancer; 2010 Dec; 55(6):1083-8. PubMed ID: 20979170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
